Published: 2022-11-28

Prescribing patterns of systemic antifungal medications in Indian patients with invasive fungal infections: a multicenter retrospective study

Lav Patel, Shreekant Sharma, Deepak Bunger


Background: Objectives of the study was to describe the utilization pattern of systemic antifungal agents in Indian patients with invasive fungal infections (IFIs).

Methods: This real-world, multicenter (127 centers), retrospective analysis included data of patients receiving systemic antifungal medications at various centers across India. The study data was collected between April 2021 and March 2022.

Results: Data of a total of 323 patients was analyzed. The mean age of patients was 54┬▒13.52 years. There was male preponderance seen in this study (72.4%). Diabetes was the most common comorbidity (36.8%) followed by concomitant diabetes and hypertension (31.9%), hypertension (9.6%) and hematological malignancies (9.6%). The most common indication occurring in >10% of the patients and for whom systemic antifungals were used included pulmonary mucormycosis (33.1%) followed by invasive candidiasis (16.1%), sepsis (13.3%) and fungal pneumonia (11.8%). In total 323 patients, the most common antifungal drug prescribed was posaconazole (38.6%) followed by anidulafungin (32.8%), caspofungin (10.5%), fluconazole (9.3%) and micafungin (8.7%). Posaconazole was most commonly used for pulmonary mucormycosis (84.8%), fluconazole for sepsis (33.3%), caspofungin for fungal pneumonia (23.5%) and anidulafungin (33.1%), and micafungin (39.3%) for invasive candidiasis.

Conclusions: This study provides real-world evidence on the demographics of Indian patients with IFIs and utilization pattern of systemic antifungals by health care physicians in clinical practice.


Antifungal, Mucormycosis, Candida, Posaconazole, Caspofungin

Full Text:



McKeny PT, Nessel TA, Zito PM. Antifungal Antibiotics. In: StatPearls. Treasure Island (FL): StatPearls Publishing. 2022 Jan-. Available at: Accessed on 2022 Aug 25.

Chakrabarti A, Chatterjee SS, Shivaprakash MR. Overview of opportunistic fungal infections in India. Nihon Ishinkin Gakkai Zasshi. 2008;49:165-72.

Sable CA, Strohmaier KM, Chodakewitz JA. Advances in antifungal therapy. Annu Rev Med. 2008;59:361-79.

Singh T, Kashyap AK, Ahluwalia G, Chinna D, Sidhu SS. Epidemiology of fungal infections in critical care setting of a tertiary care teaching hospital in North India: a prospective surveillance study. Mortality. 2014;1:19-25.

Gupta A, Sharma A, Chakrabarti A. The emergence of post-COVID-19 mucormycosis in India: Can we prevent it? Indian J Ophthalmol. 2021;69:1645-7.

Al Balushi KA, Alzaabi MA, Alghafri F. Prescribing Pattern of Antifungal Medications at a Tertiary Care Hospital in Oman. J Clin Diagn Res. 2016;10:Fc27-30.

Allen U. Antifungal agents for the treatment of systemic fungal infections in children. Paediatr Child Health. 2010;15:603-15.

Ghannoum MA, Rice LB. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev. 1999;12:501-17.

Kongkookum A, Rattanachotphanit T, Limwattananon C. Prescribing Pattern of Antifungal Agents for Superficial Fungal Infection at a District Hospital. Isan J Pharmaceutical Sci. 2017;13:39-49.

Bansal P, Baishnab S, Singla A. Drug prescribing pattern of antifungal drugs for local fungal infections in a tertiary care hospital: MAMC, Agroha. Bansal P, Baishnab S, Singla A. Drug prescribing pattern of antifungal drugs for local fungal infections in a tertiary care hospital: MAMC, Agroha. 202;2021;10:5.

Ghanem M, Zein A, Makhlouf H, Farghaly S, ElGezawy E, Mohrram A. Role of Comorbidities in Acquiring Pulmonary Fungal Infection in COPD Patients. Chest. 2016;150:915A.

Cornely OA, Arikan-Akdagli S, Dannaoui E, Groll AH, Lagrou K, Chakrabarti A et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect. 2014;20(3):5-26.

DUPIXENT® (dupilumab) injection, for subcutaneous use. Prescribing Information. Revised September, 2022. Available at: https://www. Accessed on October 12, 2022.

Demir KK, Butler-Laporte G, Del Corpo O, Ekmekjian T, Sheppard DC, Lee TC et al. Comparative effectiveness of amphotericin B, azoles and echinocandins in the treatment of candidemia and invasive candidiasis: A systematic review and network meta-analysis. Mycoses. 2021;64:1098-110.

Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62:e1-50.

Wang ES. Guideline recommendations for the prophylaxis of invasive aspergillosis in AML. Clin Adv Hematol Oncol. 2016;14:876-9.

Mousset S, Buchheidt D, Heinz W, Ruhnke M, Cornely OA, Egerer G et al. Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol. 2014;93:13-32.